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Abstract: Diabetic neuropathy affects up to 70% of diabetics, and diabetic peripheral neuro-
pathic pain (DPNP) is the most common and debilitating of the diabetic neuropathies. DPNP 
significantly reduces quality of life and increases management costs in affected patients. Despite 
the impact of DPNP, management is poor with one-quarter of patients receiving no treatment 
and many treated with medications having little or no efficacy in managing DPNP. Duloxetine 
is one of two drugs approved by the United States Food and Drug Administration for DPNP 
management. Duloxetine is a serotonin and norepinephrine reuptake inhibitor (SNRI) proven 
safe, effective, and cost-saving in reducing DPNP symptoms at a dose of 60 mg/day. Duloxetine 
doses greater than 60 mg/day for DPNP management are not recommended since they are no 
more efficacious and associated with more side effects; addition of pregabalin or gabapentin 
for these patients may be beneficial. Side effects of duloxetine are generally mild and typical 
for the SNRI class including nausea, dizziness, somnolence, fatigue, sweating, dry mouth, 
constipation, and diarrhea. Given its other indications, duloxetine is a particularly good choice 
for DPNP treatment in patients with coexisting depression, anxiety, fibromyalgia, or chronic 
musculoskeletal pain. Duloxetine treatment had no clinically significant effect on glycemic 
control and did not increase the risk of cardiovascular events in diabetes patients. However, 
duloxetine use should be avoided in patients with hepatic disease or severe renal impairment. 
Given its safety, efficacy, and tolerability, duloxetine is an excellent choice for DPNP treatment 
in many patients.
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Introduction
Diabetes is a common and costly disease in the US.1 In 2007, it was estimated that 
23.6 million US residents had diabetes.1 The prevalence of diabetes is particularly high 
in the fastest growing segment of the US population, individuals 60 years of age or 
older, with estimates of 20.9% in this group.2 Neuropathy is a common consequence 
of diabetes, affecting 60%–70% of diabetics.1 Diabetic neuropathies are a family of 
nerve disorders classified as peripheral, autonomic, proximal, and focal.3 Peripheral 
neuropathy is the most common diabetic neuropathy, estimated to occur in 47% of 
diabetics when nerve conduction testing is used for diagnosis.4 Peripheral neuropathies 
manifest with painful or painless symptoms, and many diabetic patients experience 
both. Neuropathic pain is defined by the International Association for the Study of Pain 
as “Pain arising as a direct consequence of a lesion or disease affecting the somatosen-
sory system.”5 Peripheral neuropathic pain occurs when a lesion or dysfunction affects 
the peripheral nervous system.6 The epidemiology of diabetic peripheral neuropathic Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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pain (DPNP) has not been extensively studied, as   epidemiologic 
studies have historically not differentiated between peripheral 
neuropathy patients with and without pain. However, DPNP 
is estimated to occur in 25% of all diabetics,6 and up to 50% 
of those with diabetic neuropathies.7 DPNP is particularly 
problematic in diabetic patients older than 60 years of age, 
with over half experiencing constant, daily pain that can 
substantially interfere with functional status.8
DPNP presents a unique challenge in patient management 
and should be considered a clinically distinct syndrome from 
diabetic peripheral neuropathy.9 DPNP can have debilitating 
consequences with a significant impact on patient quality of 
life (QOL) and diabetes management costs.7,10 The total 
annual direct cost of treating DPNP in the US has been 
estimated at US$237 million (2001) or US$306.08 per 
patient.9 However, the total direct and indirect DPNP-related 
costs to patients and society are much higher, estimated to 
be US$3000–$4000 (2009) per patient per year.11 In addition 
to monetary costs, DPNP can complicate diabetes treatment. 
DPNP often limits a patient’s ability to exercise or walk, 
both of which have been shown to improve glucose 
management.12,13 DPNP often significantly interferes with 
sleep,14 and lack of sleep has been shown to have a negative 
impact on glycemic control.15 Due to its impact on patient 
health, the American Diabetes Association recommends 
screening for diabetic peripheral neuropathy in all patients 
at diagnosis and annually thereafter.13
Despite the impact and prevalence of DPNP, it remains 
undertreated and poorly managed. A 2007 survey showed 
that nearly 50% of diagnosed diabetic patients had not dis-
cussed DPNP or its symptoms with their clinician,16 and a 
2004 study found that almost one-quarter of patients with 
DPNP had received no treatment for their pain.17 The DPNP-
associated pain of even those patients whose glucose levels 
are well managed often goes untreated.18 Clinicians cannot 
assume that diabetic patients with good glycemic control will 
not have DPNP, as a recent study found that 17% of patients 
with DPNP had HbA1c levels ,7%,19 and painful diabetic 
neuropathy may occur just after strict glycemic control.20,21 
Clinicians who do treat DPNP in their patients often use 
agents that are ineffective for managing neuropathic pain. 
A study of 55,686 patients with painful peripheral neuropa-
thies found that the majority received short-acting opioids 
for treatment (53.2%).17 The next largest percentage (39.7%) 
were being treated with nonsteroidal anti-inflammatory drugs 
(NSAIDs) which have no effect on neuropathic pain and are 
a significant source of renal, gastrointestinal, and cardiovas-
cular toxicity in diabetic patients. Two other drug classes 
with little or no efficacy in managing neuropathic pain, 
  benzodiazepines and selective serotonin reuptake inhibitors 
(SSRIs), were also used to treat many patients (21.1% and 
14.2% of patients, respectively). The two classes of medica-
tions with the best evidence for efficacy in treating neuro-
pathic pain, anticonvulsants and tricyclic antidepressants 
(TCAs), were used by the smallest percentage of patients 
(11.1% and 11.3%, respectively; this study predated the 
widespread use and availability of serotonin and norepineph-
rine reuptake   inhibitors [SNRIs]).
DPNP treatment options
The first and most important treatment for all DPNP patients 
is maintaining glucose concentrations within the normal range. 
Tight glycemic control can prevent progression of diabetic 
neuropathy,22,23 and multiple studies have shown that improv-
ing glycemic control can reduce pain in DPNP patients.24–26 
However, DPNP commonly occurs even in patients with 
good glycemic control,18 and pharmacologic treatments 
directed at pain are often necessary to manage DPNP. Two 
medications are currently approved by the US Food and Drug 
Administration (FDA) for the management of DPNP; dulox-
etine and pregabalin. Duloxetine is an SNRI indicated for 
the treatment of multiple diseases including major depressive 
disorder, generalized anxiety disorder, fibromyalgia, and 
chronic musculoskeletal pain.27 Duloxetine is thought to 
reduce the perception of pain by increasing the activity of 
descending pain pathways that dampen pain signals arising 
from the periphery and being relayed through the spinal cord 
dorsal horn.28 Given its other indications, duloxetine may be 
a good choice for DPNP patients with co-existing mood 
disorders and/or chronic musculoskeletal pain. Pregabalin is 
an anticonvulsant thought to reduce pain by binding to 
alpha2-delta subunits of presynaptic neuronal calcium chan-
nels and reducing the release of excitatory neurotransmitters 
involved in pain perception. In addition to DPNP, pregabalin 
is indicated for the management of post-herpetic neuralgia, 
fibromyalgia, and as an adjunct therapy for epilepsy.29
Duloxetine and pregabalin were both recommended first-
line medications for managing DPNP in consensus treatment 
guidelines.30 While not FDA indicated, TCAs and the long-
acting opioid oxycodone CR were also listed as first-tier 
medications in these guidelines based on the results of at 
least two randomized control trials (RCTs) in DPNP. 
  However, given the risks associated with opioids we recom-
mend great caution in their use particularly in older patients. 
Second-tier agents with only a single DPN RCT to recom-
mend them included the SNRI venlafaxine ER, the older Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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alpha 2-delta antagonist gabapentin, anticonvulsants 
  carbamazepine and lamotrigine, and tramadol, a weak opioid 
agonist with SNRI-activity. Other recommended treatments 
included the anticonvulsants phenytoin and topiramate, the 
antidepressants bupropion, citalopram, and paroxetine, and 
topical agents including capsaicin and lidocaine. Separate, 
newly published, DPNP treatment guidelines list pregabalin 
as the only recommended first-tier treatment choice, with 
duloxetine, venlafaxine, amitriptyline, gabapentin, valproate, 
opioids (morphine sulfate, tramadol, and oxycodone 
  controlled-release), and capsaicin all considered second-tier 
options likely to be effective.31 A third-tier recommendation 
for combination therapy with gabapentin and venlafaxine 
was based on efficacy seen in a group of DPNP patients who 
had previously failed gabapentin monotherapy.32 Given the 
differences in mechanism of action, combined use of dulox-
etine and pregabalin may be a reasonable alternative in DPNP 
patients with an inadequate response to pregabalin, but RCTs 
are needed to determine the risks and benefits of combination 
therapy with these agents.
Efficacy of duloxetine  
in the treatment of DPNP
Phase iii placebo controlled trials
Three Phase III RCTs have demonstrated the efficacy of 
duloxetine in the management of DPNP in adults (no studies 
have evaluated children) (Table 1).33–35 The first trial enrolled 
348 patients from 26 centers internationally.33 Inclusion 
criteria included patients with bilateral peripheral neuropathic 
pain caused by type 1 or type 2 diabetes mellitus who had 
mean scores of $4 when assessed for 24-hour average pain 
severity on an 11-point Likert scale and stable glycemic 
control. The Michigan Neuropathy Screening Instrument 
(MNSI) was used to confirm the diagnosis of diabetic periph-
eral neuropathy.36 Exclusion criteria for this study included 
comorbid psychiatric illness (specifically major depressive 
disorder, dysthymic disorder, generalized anxiety disorder, 
alcohol or eating disorders, mania, bipolar, disorder, or 
psychosis as defined by Diagnostic and Statistical Manual 
of Mental Disorders [DSM] IV criteria utilizing the Mini 
International Neuropsychiatric Interview [MINI]), the pres-
ence of comorbid conditions that could also cause pain (such 
as phantom limb pain or peripheral vascular disease), end-
stage renal disease (either prior transplant or ongoing dialy-
sis), substance abuse, or use of prescription opioids, 
fluoxetine, or monoamine oxidase inhibitors (MAOIs). 
The primary endpoint was change in weekly mean 24-hour 
Average Pain Scores extrapolated from daily patient diaries, 
with a 30% improvement from baseline considered a 
  therapeutic response. Responses based on 50% reduction 
from baseline were also reported. Secondary endpoints 
included change in scores on: mean weekly worst and night-
time pain from daily patient diaries, Brief Pain Inventory,37 
Short Form McGill Pain Questionnaire (a scale measuring 
various characteristics of pain ranging from 0 [none] to 3 
[severe]),38 Dynamic Mechanical (Brush) Allodynia (mea-
sured on a scale of 0 [no pain] to 3 [severe pain] after brush 
stroke administered by study personnel at a standardized 
anatomic location),39 and Hamilton Depression Rating Scale 
(17 multiple-choice item questionnaire).40 The Brief Pain 
Inventory (BPI) is a 32-question survey used for patients to 
report pain quantitatively through visual analog scales as 
well as qualitatively through questions pertaining to impair-
ment with usual daily activities due to pain.37 Further second-
ary outcomes included scores on the Clinical Global 
Impression of Severity Scale (CGI, a scale measuring the 
clinician’s impression of change in disease severity ranging 
from 1 [normal, not at all ill] to 7 [among the most extremely 
ill patients]) and Patient Global Impression of Improvement 
(PGI-I, a scale measuring patient response to therapy ranging 
from 1 [very much better] to 7 [very much worse]).41
Study treatment groups included placebo, duloxetine 
60 mg once daily (mg/day), or duloxetine 60 mg twice daily. 
The study began with a 3-day dose-escalation phase during 
which all duloxetine-assigned patients took 60 mg/day,   
followed by an increase to 60 mg twice daily in the 60 mg 
twice daily group. The average age of enrolled patients was 
58.8 years. Mean duration of diabetes in the cohort was 
13.8 years, and 99.7% were Caucasian. Demographic data 
was comparable between the study groups with the exception 
that the placebo group had a slightly higher baseline MNSI 
score (5.2 vs 4.8 and 5.0 in other groups). While this baseline 
difference was statistically significant (P = 0.036), the dif-
ference is not clinically significant since any score .2.5 is 
considered indicative of diabetic peripheral neuropathy.
Both duloxetine treatment groups met the primary trial 
endpoint with significantly greater percentages of patients 
having $30% reductions in 24-hour average pain severity 
compared with the placebo treatment group (68.14% for 
duloxetine 60 mg/day, 64.04% for duloxetine 60 mg twice 
daily and 43.36% for placebo; P , 0.001 and P = 0.002, 
respectively, for 60 mg/day and 60 mg twice daily groups 
vs placebo) (Table 1). A $50% reduction in 24-hour average 
pain was seen in 50% of patients treated with duloxetine 
60 mg/day, 39% of patients treated with duloxetine 60 mg 
twice daily and 30% of patients treated with placebo Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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(Table 1). Pain improvements were achieved by the end of 
week 1 and sustained throughout the 12-week study period 
in duloxetine-treated patients. Secondary endpoints including 
BPI,37 CGI,41 and PGI-I41 scores also demonstrated statisti-
cally significant improvement in both duloxetine treatment 
groups compared with placebo. While changes in dynamic 
mechanical allodynia scores did not achieve statistical sig-
nificance, this measure has only been validated for reproduc-
ibility by a single administrator and it is likely that 
performance differences between study sites resulted in high 
variability that limited the ability to observe treatment dif-
ferences.42 Also, given the dynamic allodynia rating at 
baseline of less than 1 on a scale of 0–3, the patients did not 
have much room for improvement on this measure (mean 
change was −0.14 for placebo and duloxetine 60 mg twice 
daily groups and −0.22 for the duloxetine 60 mg daily group). 
Path analysis was utilized to separate the direct analgesic 
effect of duloxetine 60 mg/day from pain improvement due 
to improvement in mood. This analysis concluded that over 
90% of the analgesic effect of duloxetine at either dose was 
direct compared with placebo (98% for 60 mg twice daily 
and 92.7% for 60 mg/day) and not attributable to improve-
ment in mood. This result is not unexpected since patients 
with comorbid psychiatric illness were excluded from the 
study, and it is unlikely that patients had mood symptoms 
at baseline.
The second published duloxetine DPNP trial was 
12-weeks in duration and enrolled 457 patients.34 This trial 
studied male and female patients with DPNP due to either 
type 1 or type 2 diabetes mellitus to compare the effect of 
duloxetine at doses of 20 mg/day, 60 mg/day, and 120 mg/day 
(60 mg twice daily) to placebo. Subjects were enrolled 
through multiple sites within the US, and inclusion and 
exclusion criteria were similar to the first study. The average 
age of participants in all treatment groups was approximately 
60 years, and, while genders were fairly evenly distributed, 
men outnumbered women in some treatment groups. The 
primary endpoint of the trial was change in mean weekly 
24-hour average pain scores from baseline to endpoint based 
on data extrapolation from patient symptom diaries. 
While $30% reductions in average pain scores were not 
reported, $50% reductions for all groups were given. 
  Secondary endpoints also based on symptom diary entries 
were change in mean weekly average daily and nighttime 
pain severity, and worst pain severity. BPI (severity and 
interference portions),37 CGI,41 PGI-I,41 SF-MPQ,38 Dynamic 
Allodynia,36 Short Form Health Status Survey (SF-36, con-
tains both physical and mental components to assess global 
patient function),43 and the EuroQol Group EQ-5D Quality 
of Life scale (measures impact on mood, pain, and impact 
on ability to perform various activities of daily living)44 were 
other secondary endpoints. Change in mood symptoms was 
monitored via the Beck Depression Inventory-II (BDI)45 and 
the Beck Anxiety Inventory (BAI).46
A linear, dose-dependent effect of duloxetine in reducing 
pain was seen consistently during the 12-week study period. 
The primary study endpoint of reduction in mean weekly 
24-hour average pain score from baseline was reached in 
duloxetine 60 and 120 mg/day groups, but efficacy of 
20 mg/day compared with placebo did not reach statistical 
significance and 120 mg/day was not significantly better 
than 60 mg/day. However, the percentage of patients with 
a $50% pain reduction in 24 hour average pain scores was 
significantly higher in all duloxetine treatment groups com-
pared with placebo (41% in the duloxetine 20 mg/day group, 
49% in the 60 mg/day group, and 52% in the 120 mg/day 
group vs 26% in the placebo group, P , 0.05 for all active-
treatment groups vs placebo) (Table 1). Change in BDI and 
BAI scores were used to estimate pain reduction due to 
duloxetine-mediated improvement in depression and anxiety 
symptoms, respectively. The direct analgesic effect was 
estimated to be 94.8% versus an indirect effect of 0.2% due 
to improvement in depression and 5.1% due to anxiety 
improvement in patients treated with duloxetine 60 mg/day 
versus placebo (P = 0.003). The direct analgesic treatment 
effect in this trial was similar to the 92.7% direct effect seen 
Table 1 Percentage of patients with reduced 24-hour average pain severity in duloxetine DPNP trials
Percent pain 
reduction
Trial Treatment All duloxetine groups significantly 
different from placebo Duloxetine daily dose Placebo
20 mg 60 mg 120 mg
$30% Raskin et al33 68.14% 64.04% 43.36% Yes
wernicke et al35 63% 69% 42% Yes
$50% Raskin et al33 50% 39% 30% Unreported
Goldstein et al34 41% 49% 52% 26% Yes
wernicke et al35 43% 53% 27% Yes
Abbreviation: DPNP, diabetic peripheral neuropathic pain.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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for the 60 mg/day duloxetine treatment group in the first 
treatment trial.33
The third Phase III RCT to be published investigating 
duloxetine for the management of DPNP compared dulox-
etine at doses of 60 and 120 mg/day (60 mg twice daily) to 
placebo over 12 weeks.35 This study enrolled 334 patients 
from 28 international study centers. Inclusion and exclusion 
criteria were very similar to the previous two duloxetine 
studies, with patients required to have typical DPNP pain 
(symmetric and starting in feet) daily for at least 6 months, 
MSNI scores of $3, a mean baseline score of $4 when 
assessed by 24-hour average pain severity on the 11-point 
Likert scale from the patient diary, and stable glycemic 
control. Patients with comorbid psychiatric disease based on 
DSM-IV criteria were excluded as were patients taking 
medications known to cause neuropathy, those with sub-
stance abuse disorders, or those using MAOIs or fluoxetine. 
As in the previously discussed trials, use of only certain 
additional analgesic medications during the trial were 
allowed, limited to aspirin up to 325 mg/day and acetamino-
phen up to 4 g/day. Randomization occurred after two initial 
study visits, during which baseline data was gathered. The 
primary endpoint was reduction in weekly mean 24-hour 
average pain scores calculated using patient symptom diary 
entries. Protocol-specified response at endpoint was defined 
as a $30% reduction from baseline to endpoint in the 24-hour 
average pain score. Rates for $50% reductions in 24-hour 
average pain response were also reported for all treatment 
groups. Secondary endpoints were identical to the aforemen-
tioned duloxetine studies. Pertinent demographics of the 
study population included 61.1% male, 78.1%   Caucasian, 
and a mean age of 60.7 years.
Unlike the first published study, the baseline MNSI score 
was similar amongst all groups, but the BPI average pain 
interference score was slightly lower at baseline in the pla-
cebo group (4.2 vs 4.7 and 5.0 for the 60 and 120 mg/day 
groups, respectively). This trial confirmed the findings of the 
previous two studies by showing that both duloxetine treat-
ment doses met the primary and most secondary end points 
compared with placebo. Specifically, the pain score decreased 
by an average of 1.32 in the duloxetine 60 mg/day group and 
1.44 in the 120 mg/day group compared with placebo. 
A $30% reduction in 24-hour average pain response was 
achieved by 63% in the duloxetine 60 mg/day group and 69% 
in the duloxetine 60 mg twice daily group versus 42% in the 
placebo-treatment group (P = 0.003 and P , 0.001 vs pla-
cebo, respectively). Significantly more patients in both 
duloxetine treatment groups also had $50% reductions in 
24-hour average pain response compared with placebo 
(43% for 60 mg/day and 53% for 60 mg twice daily vs 27% 
for placebo, P , 0.05 and P , 0.001, respectively). A $ 50% 
pain improvement is considered to be a “substantial” 
improvement in pain that is more significant to the day-to-day 
life of patients than a $30% improvement which is consid-
ered only a “moderately important” improvement that indi-
cates a minimal clinically significant difference.47 This trial 
also identified a significant difference not seen in the previ-
ously discussed trials between the 60 mg/day and 120 mg/day 
duloxetine groups, with the higher dosing group using sig-
nificantly less additional analgesic medications (ie, acet-
aminophen or aspirin). The two previously discussed Phase 
III trials reported significantly less additional analgesic use 
between the duloxetine and placebo treatment groups, but 
not between duloxetine dosage groups.33,34 Changes in mea-
surements of dynamic allodynia were not statistically signifi-
cant, but this is not surprising given the low average baseline 
scores (0.2 and 0.3 out of 3 for placebo and both duloxetine 
groups, respectively) and the previously discussed problems 
with inter-rater variability.42 The lack of improvement in 
HAMD17 scores was attributed to low baseline depression 
symptoms, probably a reflection of the exclusion of patients 
with comorbid major depressive disorder (MDD).
Longer-term open-label extension studies
The three previously described Phase III RCTs were each 
extended into open-label studies to monitor the efficacy of 
duloxetine in treating DPNP over longer time periods.48–50 
In the first extension trial, 237 patients who completed the 
initial study period were re-randomized to receive either 
duloxetine 120 mg/day (60 mg twice daily) or routine clinical 
care for 52 weeks.48 As in the original trial, there was a 3-day 
lead-in treatment period with duloxetine 60 mg/day before 
escalation to 60 mg twice daily in the duloxetine treatment 
group. Unlike in the RCTs, patients were permitted to reduce 
the duloxetine dose to 60 mg/day if they experienced intoler-
able treatment emergent adverse events (TEAEs). Patients 
in the routine care group received medications to treat DPNP 
based on the preference of the investigators. The most com-
monly used treatments were gabapentin (57.9%), amitrip-
tyline (22.4%), and venlafaxine (both immediate release and 
sustained release preparations were used, totaling 21.0%). 
Unlike the RCTs, the primary endpoints were changes in SF-36 
and EQ-5D scores to measure improvement in overall health 
and quality of life, respectively. The study found no significant 
difference in changes in outcome measure scores between 
patients receiving duloxetine and those receiving routing care. Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Unfortunately, no direct comparisons between duloxetine and 
specific routine-care drugs were made, likely due to the small 
number of patients in each routine-care drug group.
The second, longer-term, open-label extension study 
enrolled 337 patients after they had completed the initial 
12-week duloxetine RCT study.49 As in the first trial, one 
group of patients was randomized to receive duloxetine 
120 mg/day (60 mg twice daily) while the other received 
routine clinical care for 52 weeks. However, in this trial 
routine care was not limited to specific medications but rather 
to “… therapies that the investigator and the patient believed 
would provide optimal benefit for the patient …” Also, in 
this trial both treatment groups were permitted to use non-
medicinal therapies as desired. As in the previous open-label 
trial, changes in SF-36 and EQ-5D scores served as primary 
efficacy outcomes in the study. In contrast to the previous 
trial, data analysis showed a statistically significant improve-
ment in the SF-36 bodily pain subscale score for the dulox-
etine treatment group versus the routine care group. However, 
no other differences were found for SF-36 global or subscale 
scores between the treatment groups. While both treatment 
groups experienced significant improvement in the EQ-5D 
score from baseline, patients in the routine-care group dem-
onstrated significantly greater improvement compared with 
those treated with duloxetine. Unfortunately, no data were 
provided regarding specific treatments used in the routine 
treatment group or what doses of medications were employed 
to manage patients.
The third open-label extension study was similar in design 
to the second open-label extension trial, with 293 patients 
who had completed the initial study re-randomized to receive 
treatment over 52 weeks with duloxetine 120 mg/day (with 
usual 60 mg/day lead-in for 3 days) or routine care, with 
medications or other therapies used in the routine care group 
left to the discretion of the investigator.50 Change in SF-36 
and EQ-5D scores were again used as primary study outcome 
measures, but this study was primarily meant to evaluate 
safety and long-term tolerability rather than efficacy. The 
efficacy results of this study will be discussed in this section, 
the safety and tolerability results are covered elsewhere in 
this review. In contrast to the preceding open-label extension 
studies, this trial found a statistically significant improvement 
in the SF-36 physical component summary score as well as 
SF-36 subscale scores for physical functioning, bodily pain, 
mental health, and vitality in patients treated with duloxetine 
compared with those receiving routine care. However, as in 
the other two open-label extension trials, no differences in 
EQ-5D scores were seen between the two treatment groups.
A different study group, still associated with Eli Lilly, 
evaluated the efficacy of duloxetine in treating DPNP over 
26 weeks.51 The primary endpoint of the study was improve-
ment in BPI average pain scores. This study was an open-
label design consisting of two stages. In the first stage, 
patients were placed on duloxetine 60 mg/day (after a 1-week 
30 mg/day lead-in) for 7 weeks (weeks 1–8). In the second 
stage, patients who experienced at least a 30% improvement 
in BPI average pain rating, termed responders, continued on 
this dose for an additional 26 weeks (weeks 8–34). 
  Nonresponders (those with a ,30% improvement in pain) 
after the initial 8 weeks were moved to a “rescue” arm and 
had their duloxetine dose increased to 120 mg/day as a single, 
once daily dose that was continued for the remaining 
26 weeks. Patients in the 60 mg/day group who lost their 
treatment response between weeks 7 and 12 could be moved 
to a separate “rescue arm” wherein their duloxetine dose was 
increased to 120 mg/day during weeks 12 through 24. A total 
of 184 patients completed the initial 8-week phase, and 53.2% 
were identified as responders. Ultimately, 69 patients were 
assigned to the rescue arm. The improvement seen at 8 weeks 
(labeled “acute phase”) was sustained throughout the 
26-week period (“maintenance phase”) with the exception 
of a transient increase in BPI in the responder group at the 
week 12 assessment. Of the responders, 66.7% had a $ 50% 
improvement in pain scores at the end of the trial. Of the 
nonresponders who transitioned to the rescue arm, 31.8% 
experienced a $50% reduction in pain after their duloxetine 
dose was increased to 120 mg/day. A number of secondary 
endpoints also indicated that duloxetine treatment signifi-
cantly improved symptoms other than pain in responders, 
including global improvement, mood, walking ability, sleep, 
working ability, relations with other people, and enjoyment 
of life, and improvements made in the majority of these areas 
were maintained throughout the 34 weeks of the trial.
One other published study evaluated the safety of dulox-
etine in the treatment of DPNP.52 This trial was an open-label 
study that enrolled 449 patients from 36 international sites. In 
the study, patients were randomized to duloxetine 120 mg/day 
dosed as either 120 mg once daily or 60 mg twice daily. 
  Inclusion criteria were similar to the other studies, and all 
patients took duloxetine 60 mg once daily for 1 week before 
dose escalation. Change in BPI and CGI-S scores were the 
primary efficacy endpoints, although the primary stated goal 
of the study was to evaluate safety and not efficacy. Both 
duloxetine treatment groups demonstrated significant improve-
ment in BPI and CGI-S scores, but no significant between-
group differences were seen for duloxetine dosing groups.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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The clinical relevance of the open-label studies that used 
a duloxetine dose of 120 mg/day is questionable since the 
approved DPNP treatment dose for duloxetine is 60 mg once 
daily and no compelling data suggest increased efficacy for 
treating DPNP at duloxetine doses higher than 60 mg/day. 
However, the data derived from group means provide the 
basis for this assumption, and our experience with individual 
patients indicates that some DPNP patients may have addi-
tional clinical benefit with duloxetine doses above 60 mg/day. 
While we do not recommend routine use of duloxetine doses 
above 60 mg/day, higher doses may be beneficial to some 
patients. If clinicians chose to use higher than indicated 
duloxetine doses, we recommend possible adverse events be 
reviewed with patients and that close monitoring for adverse 
events be performed at regular intervals. It is also important 
to note that all the efficacy studies were conducted in associa-
tion with Eli Lilly, the manufacturer of duloxetine. The 
similar study design used in all trials, likely due to the Lilly 
association, is beneficial since it makes direct comparisons 
between studies possible. However, this sponsorship could 
also be a liability since the affiliation may have influenced 
the interpretation of study data and thereby biased trial 
results. A recent Cochrane Review determined that 6 DPNP 
patients would need to be treated with 60 mg/day of dulox-
etine for one patient to have a 50% reduction in pain after 
12 weeks of therapy.53 It is interesting that this number needed 
to treat (NNT) of 6 for duloxetine treatment of DPNP is 
similar to the NNT of 8 that has been shown for duloxetine 
at 60 mg/day for the management of fibromyalgia pain.53
Safety of duloxetine in DPNP 
treatment
Treatment-emergent and serious adverse 
events seen in Phase iii trials
Table 2 shows the TEAEs and serious adverse events (SAEs) 
that were associated with duloxetine treatment in the three 
Phase III DPNP RCTs.33–35 The most common TEAEs were 
nausea, dizziness, somnolence, fatigue, sweating, dry mouth, 
constipation, and diarrhea. There was a dose-related increase 
in the discontinuation rate due to adverse events (AEs) seen 
across all three duloxetine DPNP studies. One study noted 
that the most common reason for discontinuation was nausea, 
and that 86% of patients who discontinued due to AEs did 
so during the first 4 weeks of the study.33 There was no sig-
nificant difference in the percentage of patients who experi-
enced SAEs between treatment groups. For the listed SAEs, 
no concerning safety signal was detected. However, specific 
concerns about cardiovascular (CV) risk will be addressed 
in the next section.
Cardiovascular disease-related adverse 
events
There is particular concern for possible CV SAEs in diabetic 
patients treated with duloxetine. Diabetes mellitus has long 
been recognized as an independent risk factor for several 
forms of CV disease including coronary heart disease, stroke, 
peripheral arterial disease, cardiomyopathy, and congestive 
heart failure.54 Indeed, CV complications are now the leading 
causes of illness and death in the diabetic patient.55 Patients 
with diabetes are also predisposed to hypertension,56 with 
hypertension prevalence estimates ranging from 40% to 80% 
in patients with type 1 or type 2 diabetes, respectively.57,58 
Hypertension is a known risk factor for CV disease, and 
duloxetine has been associated with slight increases in mean 
heart rate and blood pressure likely due to its inhibition of 
norepinephrine reuptake.59 Duloxetine could also potentially 
increase the risk of CV-related AEs due to drug–drug 
interactions, since duloxetine is known to interact with 
multiple cytochrome P450 enzymes including CYP1A2 and 
CYP2D6.27
An Eli Lilly sponsored study pooled data from the three 
Phase III DPNP trials of duloxetine to determine if patients 
with known cardiovascular disease might be at increased risk 
for serious adverse events (SAEs).60 Of the 1024 patients 
analyzed, 762 (74.4%) had pre-existing CV disease. As 
would be expected, since patients with CV disease are more 
likely to have SAEs, a greater proportion of patients with 
pre-existing CV disease experienced SAEs compared with 
patients without known CV disease (4.6% vs 1.5%, respec-
tively). However, comparing patients with known CV disease 
to one another, duloxetine-treated patients did not have a 
higher SAE rate compared with those treated with placebo. 
In fact, the SAE rate among patients treated with duloxetine 
was actually numerically lower and just missed statistical 
significance (3.5% vs 6.7%, respectively, P = 0.06). Looking 
specifically at CV-related SAEs, eleven events were recorded 
in patients with known CV disease. Seven were reported in 
the duloxetine-treated group (two cases of hypertension and 
one case each of atrial fibrillation, myocardial infarction, 
ventricular extrasystoles, congestive heart failure, and coro-
nary artery stenosis), and four were reported in the placebo-
treated group (two cases of hypertension and one case each 
of congestive heart failure and cerebrovascular accident). By 
comparison, only one CV disease-related SAE occurred in 
patients without known cardiovascular disease (second Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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degree atrioventricular block), and this occurred in a 
  placebo-treated patient. No significant differences were seen 
in rates of CV disease-related TEAEs in trial participants 
with (8.4% in duloxetine and 9.9% in placebo) or without 
(8.6% in duloxetine and 5.7% in placebo) known preexisting 
CV disease, and no statistically significant differences in 
TEAE rates were seen between any groups (P . 0.1).
For patients on the approved duloxetine DPNP treatment 
dose of 60 mg once daily, no statistically significant increase 
in mean heart rate was seen. Also, no significant change in 
systolic or diastolic blood pressure was seen in patients with 
known CV disease. Interestingly, a statistically significant 
increase in mean diastolic blood pressure was seen in 
duloxetine-treated patients without baseline CV disease 
compared with placebo-treated patients without CV disease 
(mean change: −1.18 mmHg for placebo treatment vs 
+1.63 mmHg for duloxetine treatment, P , 0.05). However, 
it is important to note that patients with known hypertension 
entering these studies were required to have controlled blood 
pressure at baseline and this may have conferred protection 
against blood pressure increases to those with known car-
diovascular disease. Also, the meta-analyses report average 
blood pressure changes and cannot be used to predict changes 
in blood pressure and heart rate that may occur in individual 
patients. For this reason, we recommend monitoring the blood 
pressure and heart rate of patients taking duloxetine periodi-
cally regardless of their history of CV disease.
Other antidepressants, primarily the TCAs, are known to 
increase CV TEAEs by increasing the QT interval and pre-
cipitating arrhythmias. However, there is no evidence that 
clinically significant increases in QT interval are associated 
with duloxetine use. On the contrary, two separate studies 
have shown small decreases in corrected QT interval with 
duloxetine treatment.33,34
worsening of glycemic control
While selective serotonergic reuptake inhibitors (SSRIs) like 
fluoxetine can reduce hyperglycemia and increase insulin 
sensitivity, noradrenergic antidepressants like desipramine 
are known to promote hyperglycemia and insulin resistance.61 
Thus, there is concern for worsening of glycemic control in 
the diabetic patient population taking a medication like 
duloxetine that inhibits norepinephrine reuptake. To deter-
mine whether duloxetine treatment is associated with worsen-
ing glycemic control in diabetics, a meta-analysis of the three 
Phase III duloxetine DPNP trials was performed.62 This 
meta-analysis showed that during the initial 12-weeks of the 
trials patients treated with duloxetine on average had a 
  modest, but non-significant, mean increase in fasting blood 
glucose compared with those treated with placebo (+0.50 vs 
−0.11 mmol/L, respectively, P = 0.064). Also, differences 
in changes in hemoglobin A1C (HbA1C) levels were seen in 
duloxetine-treated patients compared to those treated with 
placebo. However, in the 52-week open label extension phase 
of these studies a statistically significant increase in mean 
fasting blood glucose (+0.67 vs −0.64 mmol/L, P , 0.001) 
and HbA1C (+0.52% vs +0.19%, P , 0.001) levels were seen 
in duloxetine-treated patients compared with those receiving 
routine care.62 While the average changes were small, larger 
changes could be seen in individual patients. For this reason, 
diabetes patients placed on duloxetine for management of 
their DPNP should be monitored for worsening of their 
glycemic control. However, from the available data it appears 
the risk of worsening glycemic with duloxetine treatment at 
the indicated DPNP treatment dose is small.
General laboratory abnormalities
Modest increases in liver function tests, bicarbonate and 
inorganic phosphorus associated with duloxetine treatment 
were seen in the three Phase III duloxetine DPNP trials but 
were not deemed by the authors to be clinically significant 
(Table 2). However, these figures compare mean changes 
and cannot be used to predict changes that may occur in 
individual patients. Hepatic failure, sometimes fatal, has been 
reported in patients treated with duloxetine.27 For this reason, 
patients should have baseline liver function testing to look 
for any liver disease. Duloxetine should not be used in 
patients with evidence of chronic liver disease or substantial 
alcohol use and we recommend periodic liver function testing 
be performed while patients are on duloxetine treatment. 
Since many patients with diabetes have renal disease that 
can affect electrolyte levels, and cases of hyponatremia have 
been reported with duloxetine use,27 we also recommend 
periodic monitoring of electrolytes while patients are treated 
with duloxetine particularly in the elderly who are at 
increased risk of electrolyte abnormalities.
One study found an increase in total and LDL cholesterol 
associated with duloxetine treatment,33 but this finding was 
not substantiated by the other two trials (Table 2). Regarding 
lipids, a meta-analysis of the three Phase III duloxetine DPNP 
trials showed that during the initial 12 weeks of the trials, 
duloxetine treatment was associated with a small decrease 
in serum triglycerides and small increases in high-density 
lipoprotein (HDL) cholesterol, low-density lipoprotein 
(LDL) cholesterol, and total cholesterol.62 However, change 
in HDL cholesterol level was the only measure in Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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  duloxetine-treated patients that was statistically different 
from that seen in placebo-treated patients, and the difference 
was not clinically significant (+0.03 vs 0.00 mmol/L, respec-
tively, P = 0.008).62 Similarly, during the 52-week open-label 
extension phase of the DPNP duloxetine trials, there was a 
small numeric increase in serum levels of triglycerides, total 
and LDL cholesterol associated with duloxetine treatment, 
but only the change in total cholesterol levels was signifi-
cantly different in duloxetine-treated patients compared with 
those who received routine care and once again the difference 
was not clinically significant (+0.06 vs −0.16 mmol/L, 
respectively, P = 0.005).62 While HDL cholesterol levels 
slightly decreased in the duloxetine-treated group in the 
extension phase, levels in the routine care group dropped 
significantly more (−0.01 vs −0.08 mmol/L, respectively, 
P = 0.002).62 Taken together, there is no evidence that dulox-
etine treatment significantly impacts lipid levels in patients 
with DPNP. However, since diabetic patients are at increased 
risk for lipid abnormalities and CV events, evaluation and 
management of lipid abnormalities should be a part of routine 
care in these patients.
weight changes
Weight loss was seen in one of the Phase III duloxetine DPNP 
studies.33 In this study, treatment with duloxetine at a dose 
of 60 mg bid was associated with a mean weight loss of 
0.9 kg compared with placebo (P = 0.006). No significant 
mean weight change was seen in patients treated with the 
approved duloxetine dose of 60 mg/day.33 Pooled analysis 
of the three duloxetine DPNP treatment studies showed that 
duloxetine treatment was associated with an initial weight 
loss compared with placebo in the first 12 weeks of the trials 
(mean change −1.03 vs +0.03 kg, respectively, P , 0.001).62 
However, weight loss was not maintained in the 52-week 
extension study and, on average, patients in both duloxetine 
treatment and routine care groups gained weight (+0.31 and 
+0.49 kg, respectively, P = 0.531).62
Fracture risk
SSRIs have been linked to increased fracture risk due to their 
effects on bone metabolism.63 However, to our knowledge, 
increased fracture risk has not been linked to the use of SNRIs 
like duloxetine. There were no reports of fractures in the 
three Phase III duloxetine DPNP trials or open label exten-
sion studies.33–35,64–66 However, diabetic patients are known 
to be at increased risk for fractures compared with nondiabet-
ics for a given bone mineral density,65 and all diabetics should 
be monitored for development of osteoporosis and 
  aggressively managed if fragility fractures occur to prevent 
future fractures as part of routine care.
Patient monitoring
Baseline and periodic monitoring of blood pressure, pulse, 
electrolytes, renal, and liver function, and serum lipids are 
recommended while patients are being treated with 
  duloxetine. Although no cases of suicidality were observed 
in the duloxetine DPNP trials, treatment with antidepressants 
is known to increase the risk of suicidality in some patients.66 
Since suicidality is more likely to occur in patients with 
underlying psychiatric disorders, particularly bipolar disor-
der, it is recommended that patients with depressive symp-
toms be evaluated for bipolar disorder prior to initiating 
duloxetine and that patients treated with duloxetine be 
closely monitored for unusual changes in behavior or 
  suicidality.27
Contraindications
According to the package insert,27 duloxetine should not be 
administered to patients with any hepatic insufficiency. 
Also, duloxetine is not recommended for patients with 
severe renal impairment (defined as an estimated creatinine 
clearance of ,30 mL/min). Finally, use should be avoided 
in patients with uncontrolled acute narrow angle glaucoma. 
Also, based on our clinical experience, we recommend that 
glaucoma patients be regularly monitored for changes in 
intraocular pressure while they are being treated with any 
selective serotonin reuptake inhibitor (SSRI) or SNRI.
Drug interactions
Concomitant use of MAOIs with all serotonergic drugs, 
including duloxetine, is contraindicated. Duloxetine should 
be used cautiously in combination with other serotonergic 
drugs, including TCAs, SSRIs, triptans, antipsychotics, or 
other dopamine antagonists, in order to decrease the risk 
of serotonin syndrome or neuroleptic malignant syndrome.27 
Potent CYP1A2 and CYP2D6 inhibitors should also be 
avoided in combination with duloxetine as this may result 
in increased serum concentrations of duloxetine. Similarly, 
drugs with a narrow therapeutic index that are metabolized 
by the P450 CYP2D6 enzyme should be used with caution 
in combination with duloxetine since duloxetine may 
increase plasma concentration of these drugs. TCAs, 
phenothiazines, and type 1C antiarrhythmics should also 
be used with caution in combination with duloxetine. 
Thioridazine should not be used in combination with 
duloxetine.27Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Patient acceptability
There are several medications currently available with pur-
ported benefit in the treatment of DPNP, with duloxetine 
among the newer of these agents.30,31 While no published 
head-to-head trials comparing DPNP medications exist, 
multiple cost-effectiveness analyses have been performed 
on available data to determine the relative cost effectiveness 
of different DPNP medications. The first cost-utility com-
parison was formulated by an independent group of investi-
gators at the University of Rochester in New York to 
determine the relative cost effectiveness of numerous medica-
tions used to treat DPNP.67 This analysis was undertaken 
without industry support or ties and therefore provides a rare 
third-party analysis that is likely to be objective. Making use 
of both published and unpublished data, a decision analytic 
model was used to compare desipramine 100 mg/day, gaba-
pentin 2400 mg/day, pregabalin 300 mg/day and duloxetine 
60 mg/day for the management of DPNP in terms of quality 
adjusted life years (QALY). Desipramine and duloxetine 
were found to be more efficacious and also less expensive 
compared with pregabalin and gabapentin. Specifically, 
duloxetine was calculated as having an incremental cost-
effectiveness ratio of US$47,700 per QALY compared with 
desipramine, which was the reference medication against 
which the others were measured. While another cost- 
effectiveness analysis of open-label extension studies showed 
a benefit for the use of duloxetine in DPNP treatment com-
pared with other treatments,68 the results of this analysis 
should be interpreted cautiously since the analyzed studies 
used higher than indicated duloxetine doses (120 mg/day) 
and the analysis was financed by Eli Lilly, the manufacturer 
of duloxetine.
A meta-analysis has also been used to indirectly compare 
the effectiveness of duloxetine, pregabalin, and gabapentin 
for the treatment of DPNP.69 These authors, who disclosed 
ties to Eli Lilly at the time of publication, identified no sta-
tistically significant difference in efficacy or tolerability 
between duloxetine and gabapentin. While duloxetine and 
pregabalin had similar efficacy in reducing 24-hour pain 
scores, duloxetine was found to be superior to pregabalin 
with regards to TEAEs (specifically dizziness), whereas 
pregabalin was superior to duloxetine in improving global 
disease symptoms as assessed by PGI-I/C scores. The authors 
concluded that all three medications provided comparable 
efficacy and tolerability in DPNP patients and that selection 
among the three agents should be based on individual patient 
tolerance and preference. Based on its other indications and 
our clinical experience, we recommend duloxetine as a first 
line treatment for DPNP patients with coexisting depression 
or anxiety disorders and pregabalin or gabapentin as the 
first-line DPNP therapy in patients with concomitant sleep 
problems or seizure disorders.
Eli Lilly researchers investigating health care costs and 
adherence in patients taking duloxetine for DPNP using 
retrospective data found that a dose of 60 mg/day was 
associated with maximal adherence and less health care 
costs over a 12-month study period compared with higher 
or lower duloxetine doses.70 However, the significance of 
this data is questionable since 60 mg/day is the indicated 
dose of duloxetine for DPNP treatment,27 and all longer-
term tolerability data for safety have been measured using 
120 mg/day of duloxetine.48–50 Other retrospective data has 
demonstrated that DPNP patients who use duloxetine con-
tinuously for 12 months had lower opioid use than either 
those who used duloxetine intermittently or who were 
treated with other typical medical therapies for DPNP 
(specifically, TCAs, venlafaxine, gabapentin, and 
pregabalin).71 Since opioids have significant TEAEs, such 
as somnolence and constipation, and a recent study found 
that older adults treated with opiates had increased risk for 
cardiovascular events, fracture risk, safety events requiring 
hospitalization, and risk of all-cause mortality,72 minimizing 
opioid use is likely to be beneficial for overall patient health 
and well-being.
Cessation of duloxetine therapy can result in discontin-
uation-associated adverse events (DEAEs), typified by the 
discontinuation syndrome that is often seen when abruptly 
stopping drugs that inhibit serotonin reuptake.73 Eli Lilly 
researchers pooled data from patients after their participation 
in duloxetine treatment studies for DEAEs and found that 
DEAEs occurred in 44.3% of patients who abruptly stopped 
duloxetine.74 The most common DEAE was dizziness 
(12.4%), followed by nausea (5.9%), and headache (5.3%). 
Other less commonly seen DEAEs included paresthesias, 
irritability, and nightmares. However, it is important to note 
that the majority of DEAEs occurred in patients treated with 
120 mg/day of duloxetine; the rates of DEAEs in patients 
taking # 60 mg/day of duloxetine were similar to those seen 
in patients treated with placebo. Also, the majority of DEAEs 
(65%) resolved relatively quickly, within 7 days of duloxetine 
discontinuation. Finally, these DEAE rates were derived from 
duloxetine studies in patient with major depressive disorder 
and the applicability to DPNP patients is unknown. However, 
due to possible DEAE risk, a gradual dose reduction is rec-
ommended in patients who must discontinue duloxetine 
therapy regardless of the indication.27Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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A common issue that often arises in initiating duloxetine 
treatment is the best method to switch patients from an SSRI 
to duloxetine, specifically whether the SSRI should be gradu-
ally or abruptly discontinued. This issue was studied in a 
multicenter, open-label, randomized trial conducted in 
Europe.75 The study randomized 368 patients with major 
depressive disorder taking an SSRI to either begin a 2-week 
gradual discontinuation or abruptly stop their SSRI at the 
time duloxetine 60 mg/day was started. The trial found no 
significant difference in the TEAE rates between gradual and 
abrupt discontinuation groups, and there were no significant 
differences in the adverse event discontinuation rate overall 
or the rate of study discontinuation due to any particular 
adverse event. Also, changes in vital signs, laboratory tests, 
and weight were not significantly different between the two 
discontinuation groups. Based on these data, there appears 
to be no need to taper an SSRI upon initiation of duloxetine 
treatment.
Other issues that commonly arise in initiating duloxetine 
treatment are the timing of administration and optimal starting 
dose. The duloxetine prescribing information gives no recom-
mendation on the timing of duloxetine treatment. However, 
since nausea, dizziness, and somnolence were common TEAEs 
seen in DPNP trials,27 we typically recommend that patients 
take duloxetine with their evening meal or with a bedtime 
snack. The duloxetine prescribing information recommends 
starting with the indicated 60 mg once daily dose.27 However, 
in our experience, many patients do not tolerate starting dulox-
etine at the indicated dose. The duloxetine prescribing infor-
mation states that: “For patients for whom tolerability is a 
concern, a lower starting dose may be considered. Since dia-
betes is frequently complicated by renal disease, a lower 
starting dose and gradual increase in dose should be considered 
for patients with renal impairment.”27 Based on the efficacy 
for reducing pain shown by duloxetine 20 mg/day in DPNP 
patients,34 we typically start all patients on this dose. We 
recommend that patients are monitored for therapeutic 
response and tolerability at weekly or bi-weekly intervals, and 
that the dose is increased in 20-mg increments as needed and 
tolerated, to a maximum of 60 mg/day.   However, since the 
smallest dose Eli Lilly samples is 30 mg, we would start with 
30 mg/day if the patient requires samples.
Conclusion and key points
1.  Duloxetine at 60 mg/day is a safe and effective FDA-
approved treatment for DPNP. Duloxetine is cost-saving 
compared with other approved and non-approved 
  treatments for DPNP.
2.  Given its other indications, duloxetine is a particularly 
good choice for DPNP treatment in patients with coexist-
ing major depressive disorder, generalized anxiety dis-
order, fibromyalgia, or chronic musculoskeletal pain.
3.  Duloxetine use should be avoided in patients with hepatic 
impairment, severe renal disease, or serious or unstable 
medical conditions.
4.  Routine use of duloxetine doses greater than 60 mg/day 
for DPNP management are not recommended since 
higher doses are no more effective, and are associated 
with more TEAEs and worse tolerability. In patients with 
an inadequate therapeutic response to duloxetine 
60 mg/day, addition of pregabalin or gabapentin is 
recommended.
5.  TEAEs with duloxetine are typical for SNRI medications 
and include nausea, dizziness, somnolence, fatigue, sweat-
ing, dry mouth, constipation, and diarrhea. Nausea, the most 
common reason for discontinuation of duloxetine in clinical 
trials, can be limited by taking duloxetine with food.
6.  Duloxetine treatment did not increase the risk of CV events 
in diabetic patients. However, CV risk factors should be 
regularly monitored and minimized in all diabetics.
7.  No clinically significant mean changes in measures of 
glycemic control were seen in duloxetine-treated patients. 
However, since changes in individual patients cannot be 
predicted, regular monitoring of blood glucose and HbA1c 
levels are recommended in diabetic patients treated with 
duloxetine.
8.  To maximize tolerability, we recommend starting dulox-
etine at 20 mg/day with the evening meal or a bedtime 
snack and increasing in 20-mg increments as needed and 
tolerated in weekly or bi-weekly increments to a maxi-
mum dose of 60 mg/day.
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